New drug trial aims to shrink kidney tumors and save organs
NCT ID NCT07265947
Summary
This study is testing an oral drug called dabogratinib (TYRA-300) for adults with a specific type of low-grade cancer in the upper urinary tract. The main goal is to see if the drug can completely eliminate the tumors, potentially allowing patients to avoid major kidney-removal surgery. Researchers will also closely monitor the drug's safety and how well it helps preserve kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Urology
RECRUITINGJeffersonville, Indiana, 47130, United States
-
Urology Associates, P C
RECRUITINGNashville, Tennessee, 37209-4035, United States
Conditions
Explore the condition pages connected to this study.